Monday, June 22, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 701 of 1,261

  1. US 9302120

    Spiro-oxindole MDM2 antagonists

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  2. US 9303258

    Method and compositions comprising small RNA agonist and antagonists to modulate inflammation

    The Regents of the University of California · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  3. US 9302085

    Methods and compositions for facilitating arterial access

    The Regents of the University of California · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  4. US 9301947

    Ryanodine receptor inhibitors for treatment of T-cell mediated disorders

    The Regents of the University of California · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  5. US 9303087

    Monoclonal antibodies that inhibit the Wnt signaling pathway and methods of production and use thereof

    The Board of Regents of the University of Oklahoma · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  6. US 9303080

    Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells

    The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  7. US 9301960

    Methods for inhibiting redox-sensitive GTPases

    The Board of Regents of the University of Texas System · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  8. US 9303260

    UNA duplex oligomers for therapeutics

    ARCTURUS THERAPEUTICS, INC. · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  9. US 9303064

    Peptide inhibiting matrix metalloproteanases activity and use thereof

    CAREGEN CO., LTD. · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  10. US 9303000

    Olefin containing nuclear transport modulators and uses thereof

    Karyopharm Therapeutics Inc. · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  11. US 9303077

    Peptide composition for cancer treatment by inhibiting TRPV6 calcium channel activity

    Soricimed Biopharma Inc. · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  12. US 9301976

    Compositions comprising perivascular stem cells and nell-1 protein

    The Regents of the University of California · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  13. US 9304124

    Compact multifunctional ligand to enhance colloidal stability of nanoparticles

    United States of America as represented by the Secretary of the Air Force · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  14. US 9303066

    Treatments for gastrointestinal disorders

    IRONWOOD PHARMACEUTICALS, INC. · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  15. US 9302981

    Synthesis, methods of using, and compositions of cycloalkylmethylamines

    REVIVA PHARMACEUTICALS, INC. · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  16. US 9303061

    Spiro compounds as Hepatitis C virus inhibitors

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  17. US 9302010

    Stable formulations for parenteral injection of peptide drugs

    XERIS PHARMACEUTICALS, INC. · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  18. US 9303002

    Compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  19. US 9302002

    Etanercept formulations stabilized with combinations of sugars and polyols

    Coherus BioSciences, Inc. · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted

  20. US 2016089368

    TREATMENT OF MASTOCYTOSIS WITH MASITINIB

    AB SCIENCE [FR] · Granted Mar 31, 2016 · Expires Mar 26, 2036

    granted

  21. US 9297008

    Small activating RNA molecules and methods of use

    The Regents of the University of California · Granted Mar 29, 2016 · Expires Mar 24, 2036

    granted

  22. US 9295674

    Metalloporphyrin neurological treatments

    The Regents of the University of Colorado, a Body Corporate · Granted Mar 29, 2016 · Expires Mar 24, 2036

    granted

  23. US 9295724

    Stable formulations for parenteral injection of peptide drugs

    XERIS PHARMACEUTICALS, INC. · Granted Mar 29, 2016 · Expires Mar 24, 2036

    granted

  24. US 9296701

    DNA-PK inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Mar 29, 2016 · Expires Mar 24, 2036

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.